Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Socie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Cancer J
Asıl Yazarlar: Gilleece, Maria H., Shimoni, Avichai, Labopin, Myriam, Robinson, Stephen, Beelen, Dietrich, Socié, Gerard, Unal, Ali, Ganser, Arnold, Vitek, Antonin, Sengeloev, Henrik, Yakoub-Agha, Ibrahim, Tholouli, Eleni, Polge, Emmanuelle, Mohty, Mohamad, Nagler, Arnon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://ncbi.nlm.nih.gov/pubmed/33980810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00479-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller